Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

http://www.wikidata.org/entity/Q33881977

about

Sphingolipids: a potential molecular approach to treat allergic inflammation Importance of Apolipoprotein A-I in Multiple Sclerosis Immune interventions in stroke Sphingosine 1-phosphate receptor modulators in multiple sclerosis Remyelination therapy for multiple sclerosis Lysophospholipids and their receptors in the central nervous system Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis Fingolimod phosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons Therapeutic decisions in multiple sclerosis: moving beyond efficacy Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome Sphingosine-1-Phosphate Metabolism and Its Role in the Development of Inflammatory Bowel Disease Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Fingolimod treatment in multiple sclerosis leads to increased macular volume.Infection risk in patients on multiple sclerosis therapeutics.The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration PET Study of Sphingosine-1-Phosphate Receptor 1 Expression in Response to Vascular Inflammation in a Rat Model of Carotid Injury.Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.An update on the biology of sphingosine 1-phosphate receptors.Fingolimod and cardiac risk: latest findings and clinical implications Drug therapy for multiple sclerosis.Lysophospholipid receptor nomenclature review: IUPHAR Review 8.FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis.Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile M tuberculosis in the adjuvant modulates time of appearance of CNS-specific effector T cells in the spleen through a polymorphic site of TLR2 Impact of an immune modulator fingolimod on acute ischemic stroke.Oral disease-modifying therapies for multiple sclerosis.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

P2860

Q21296721-F66894CD-B53B-4C27-9A27-6175E1B6553C Q26774792-7EC4ACD8-A2E1-422D-86B1-9AD96ECC7132 Q26797993-EE2743A6-2FD6-4398-80A9-491D4B035D13 Q26799440-0C32F2FB-3F55-41EC-AE91-C084853F7F39 Q26824246-50298746-138B-4457-86A2-1C73D7075E48 Q26859168-0861C414-92FB-4420-B702-CB67557C0DA2 Q26999417-4AA09C30-407C-4657-9F26-D81589F38ECE Q27011473-E187FF82-D64B-4B91-90F2-B704FD4B7B13 Q28078744-AA4385F0-0034-46CD-ADB5-A249A4EF15B2 Q28087414-C1E7F090-1A15-4BF0-AE68-516DA3E3A36D Q28486184-AC173D8F-3EE7-45EF-8DA6-9853C0273D79 Q28541039-006235B4-6FE9-471E-935A-DDB86874F6C1 Q28546716-572067C3-EDD9-4373-B4A5-7D7CE464D613 Q28554434-574CF5C5-7F4C-4306-B7BD-64A2E29BCB4E Q30235011-6EFC7A15-8E90-4765-A0BD-09A318F6A0E3 Q30458371-8498130D-DA2B-4721-B9BB-CF7F04E14CED Q30486707-9667F26B-0A1B-492F-85A9-79C5BA89D904 Q30537200-AA5DB546-79DF-4057-AFDF-4E81C2918B14 Q30908652-C946A81D-5EDE-49B5-A1B9-E1844CA4A4F0 Q33614909-42CB4742-9109-42E1-BF76-CB5C3106230F Q33639041-4B592FAB-A444-4558-A5FD-ABFC14F48649 Q33753317-F39EDD0B-A01B-4E94-A8BD-8B264EFAE123 Q33755345-ACBA2BB2-4410-42BC-86D5-41BFF0DC894E Q33756197-701ECE84-32F5-44DA-ACFF-A286BC835BD3 Q33759830-08E55D35-ABB5-4CB0-B738-B14B2A08A365 Q33784217-DC58F0CD-4570-411D-B5BD-E0E1D2D143A0 Q33795454-FDCED90F-5053-4563-829B-219AABB308B2 Q33872502-EA94B716-ADC4-466D-BD6D-F6EEBF7BBABA Q33945064-16B0EE37-1645-425C-B700-EF0DC81CF26D Q33949504-F0EB3D92-0835-4D71-9A20-769E05412F60 Q33990246-3CC145F4-0C20-4A7A-B361-3BD8F3A595E0 Q34025135-0995891E-3919-40B5-B038-7308BC8F869C Q34105944-1A0F29EA-6D9D-4001-BDA3-7FC423931B5F Q34296297-8B509ADC-B10A-4C44-B1BF-DEC7F71556E3 Q34314035-50670422-305E-4AAC-9021-717ED9768AE3 Q34408450-E95CBFEE-784D-4714-B632-1889FCC9FFE3 Q34586313-C808085A-4A26-4040-90B9-5D7BBE48EB4C Q34792950-4D12BE19-6E6D-4D39-A058-4C4C80D45834 Q34996562-5B19EA5F-FDCB-40B9-88A2-5D3369727DB9 Q35551835-59973D78-078A-48F1-A8EF-949A7D37C08D

P2860

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

http://www.wikidata.org/entity/Q33881977

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@ast

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@en

type

label

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@ast

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@en

prefLabel

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@ast

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@en

P1433

Q33881977-FC5B3504-1AD3-4F3C-8B7C-285D8AC4011E

P1476

Q33881977-8808F040-07B9-4EED-B14C-577C0A1B1531

P2093

Q33881977-5E70449C-ABD4-4073-BA9C-A19E5DE7F683

Q33881977-AEEB7910-9A30-4EBF-8764-1E5C9AD1AF3C

P2860

Q33881977-00AE8169-8EFE-4EDB-B7C6-85BCC91FC776

Q33881977-02E51D10-E96A-4D56-BE25-3E60C9C610A5

Q33881977-06468197-D59B-406B-A73C-900C8FAAD323

Q33881977-0FBB9CDA-DC2F-4EF5-ABB8-3AA5CABAB674

Q33881977-10E0427D-E482-4F6C-9685-5AE7E2E03A61

Q33881977-11A2FC48-3702-4025-B82E-FC1326264D9A

Q33881977-17131AB3-026A-47C6-A529-79535B5D8D88

Q33881977-188649A6-9A64-4AB5-8802-B9002509F126

Q33881977-1B2BCEE2-304D-48FF-9F4B-EB7547EF83C4

Q33881977-1B35EE0F-798E-49C9-8841-5D0EAB57192C

P304

Q33881977-F41DD04F-761C-454D-8781-B1555FD29AC8

P31

Q33881977-3C9D1716-04FA-4821-A24A-63E3B19A5572

P356

Q33881977-3FA921F8-2925-4285-A38F-BBA77C2001CC

P433

Q33881977-AFAC2458-D51D-4C04-BD8A-EB926EAE66A3

P478

Q33881977-8202EE83-7B00-4C0B-9074-1F6F6313A5D5

P577

Q33881977-3D4F8BE8-F7DC-48B8-B5B9-2C0007911173

P698

Q33881977-E76BFA93-C39C-40E8-8B3F-4BE5A57A13AE

P921

Q33881977-A6DAB62A-E6AD-40AE-B445-CC7691871532

P356

P1433

Annals of Neurology

P1476

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

@en

P2093

Jeffrey A Cohen

http://www.w3.org/2001/XMLSchema#string

Jerold Chun

http://www.w3.org/2001/XMLSchema#string

P2860

Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation

Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways

Characterization of a novel sphingosine 1-phosphate receptor, Edg-8

Cell type-specific localization of human cardiac S1P receptors

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Astrocytes in multiple sclerosis: a product of their environment

Sphingosine-1-phosphate signaling in the cardiovascular system

Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218

Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors

P304

759-777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22426

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21520239

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis